Secretary Robert F. Kennedy Jr. of the Department of Health and Human Services has committed to improving the health of Americans, with a particular emphasis on reducing health burdens among children. Despite this, the department recently removed the Advisory Committee on Newborn and Child Genetic Disorders.
For the past 15 years, the Advisory Committee on Hereditary Disorders in Newborns and Children has played a crucial role in recommending which conditions should be included in the universal screening panel for newborns to the health and human services secretaries.
Kennedy’s focus has been on tracing the origins of a broader spectrum of pediatric diseases such as autism, asthma, and obesity, but rare diseases, mostly genetic, remain a significant public health concern. In the United States, around 15 million children have rare diseases, most of which are genetic.
Screenings of newborns identify about 14,000 babies each year with potentially life-threatening conditions, according to the National Agency for Rare Disability (NORD). Early diagnosis at birth provides parents with valuable intervention opportunities, usually most effective before symptoms manifest.
While individual states determine which conditions to screen for, most follow the federally recommended uniform screening panel. Volunteer scientists and medical professionals on the advisory board primarily shape the screening panel with their recommendations.
Allison Herrity, senior policy analyst at NORD, expressed disappointment at the dissolution of the committee and its impact on the process of adding new conditions to the screening panel.
The Internal HHS email reviewed by NBC News confirmed the abrupt end of the committee on April 3, without any explanation. This decision has left room for speculation and hope that the committee may be reinstated to address the pressing need for identifying and treating rare genetic disorders in newborns.
Dr. Sean McCandless, Director of Genetics and Metabolism at Colorado Children’s Hospital, emphasized the importance of early diagnosis and treatment, especially for conditions like MLD and DMD, which have available therapies to improve patients’ quality of life.
However, the removal of the advisory committee poses a threat to the inclusion of new conditions in the Universal Panel. Without a structured approach like the committee, ensuring comprehensive and evidence-based screening for new conditions becomes challenging.
McCandless and other healthcare professionals have appealed to Kennedy to reinstate the advisory board to align with his vision of a healthier America. Advocates are concerned about the future of universal screening and fear disparities between states in offering comprehensive screenings.
They stress the importance of an independent body like the advisory committee to ensure that screening recommendations are based on scientific evidence rather than external influences.
There is a call for a more streamlined process for adding conditions to the screening panel to keep pace with advancements in treatments and medical knowledge, ultimately benefiting children and families affected by rare genetic disorders.
Source: www.nbcnews.com
